MurdoC schreef op 3 februari 2021 20:13:
Ncyt mcap £580 million vs Braveheart £15 million
Paraytec's target is to detect less than 1000 virions per millilitre of sample, which would represent a market leading performance"
"Detection tests show that Paraytec's aptamer based viral capture system completely traps target material in 300 seconds or less, confirming that its test platform is on target to deliver a test result within a five-minute timeframe"
"We are very pleased with the rapid performance of our sample capture device. Together with the analytical sensitivity and speed of the optical system, we are on track to deliver a robust test that will support the level of infection control required globally."
"We are very pleased with the rapid performance of our sample capture device" MEANING capture device is well on TRACK and to DELIVER what paraytec / professor have been saying all this time....looks like we are TUNING this device to make it even better and FASTER....WATCH THIS SPACE.....dont get caught out on next rns....which can come much earlier than late FEB
"Together with the analytical sensitivity and speed of the optical system, we are on track to deliver a robust test that will support the level of infection control required globally."
"The objective is to develop a portable test, which can generate a result in a matter of minutes from a swab provided at the test location and which requires no specialist skills for its operation. If successful, it could be used in airports, transport hubs, large workplaces and similar settings, where rapid screening of large numbers of people for presence of COVID-19 or any future emerging pandemic, is required."
braveheartgroup.co.uk/investments/nl.investing.com/equities/braveheart-...